查詢結果分析
來源資料
相關文獻
- 心房纖維顫動併冠心症之案例報告
- Dabigatran(Pradaxa®)--半個世紀後再見口服抗凝血新藥
- 心房纖維顫動(Atrial Fibrillation)的藥物治療
- 心房纖維顫動(Atrial Fibrillation)的藥物療法
- 心房性心律不整的最新研究及治療
- Clinical Manifestations of Ischemic Bowel Disease
- Polymorphisms of the Apolipoprotein B3' Variable Number of Tandem Repeats Region Associated with Coronary Artery Disease in Taiwanese
- 心房纖維顫動之最新治療
- 以臨床實用觀點論急救流程之改變
- Warfarin的交互作用
頁籤選單縮合
題 名 | 心房纖維顫動併冠心症之案例報告=A Case Report with Atrial Fibrillation and Coronary Heart Disease Taking the Anticoagulant Agent |
---|---|
作 者 | 張凱越; 王明賢; | 書刊名 | 藥學雜誌 |
卷 期 | 34:3=136 2018.09[民107.09] |
頁 次 | 頁102-107 |
分類號 | 415.318 |
關鍵詞 | 心房纖維顫動; 冠心症; 抗凝血藥物; Atrial fibrillation; Coronary heart disease; Anticoagulant agents; |
語 文 | 中文(Chinese) |
中文摘要 | 心房纖維顫動可能會增加病人發生心臟衰竭或中風的風險,如同時罹患冠狀動脈 心臟病,其中風的風險盛行率會隨個案年齡而逐漸增加;依常見臨床指引建議,針對 心房纖維顫動併有冠狀動脈心臟病的病人需同時使用抗凝血劑與抗血小板藥品,但兩 類藥品併用可能會增加出血的風險。本案例是一位61歲診斷有心房纖維顫動及冠心症 的女性,經醫療團隊評估其中風風險 CHA2DS2-VASc 為5分 (屬高中風風險)、出血風 險 HAS-BLED 為2分 (屬低出血風險)、藥物評估 SAM-TTR2R2為4分 (適合非 vitamin K 拮抗作用口服抗凝血劑),透過臨床實證查證及團隊討論,共識針對合併有心房纖維顫 動與冠狀動脈心臟病病人之合宜口服抗凝血劑與抗血小板藥品,希冀能獲得最佳的治 療效益,並降低出血副作用的風險。 |
英文摘要 | Patients with atrial fibrillation may have a higher risk of stroke or heart failure. The prevalence of atrial fibrillation in patients with coronary artery disease is increased with age. According to major guidelines, such patients should take oral anticoagulants in combination with anti-platelet agents for the reduction of the risk of thrombosis and stroke, but also be monitored for potential bleeding risk. This is a case of a 61 years old woman who was diagnosed coronary heart disease and atrial fibrillation. Her CHA2DS2-VASc Score is 5 points, HAS-BLED Score is 2 points and SAM-TTR2R2 Score is 4 points. Based on these risk factors, we will discuss about the pharmacotherapeutic treatment of atrial fibrillation in patients with coronary artery disease. |
本系統中英文摘要資訊取自各篇刊載內容。